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Malignant pleural mesothelioma (MPM) is an aggressive inflammatory cancer with a poor
survival rate. Treatment options are limited at best and drug resistance is common. Thus,
there is an urgent need to identify novel therapeutic targets in this disease in order
to improve patient outcomes and survival times. MST1R (RON) is a trans-membrane
receptor tyrosine kinase (RTK), which is part of the c-MET proto-oncogene family. The
only ligand recognized to bind MST1R (RON) is Macrophage Stimulating 1 (MST1), also
known as Macrophage Stimulating Protein (MSP) or Hepatocyte Growth Factor-Like
Protein (HGFL). In this study, we demonstrate that the MST1-MST1R (RON) signaling
axis is active in MPM. Targeting this pathway with a small molecule inhibitor, LCRF-0004,
resulted in decreased proliferation with a concomitant increase in apoptosis. Cell cycle
progression was also affected. Recombinant MST1 treatment was unable to overcome
the effect of LCRF-0004 in terms of either proliferation or apoptosis. Subsequently, the
effect of an additional small molecular inhibitor, BMS-777607 (which targets MST1R
(RON), MET, Tyro3, and Axl) also resulted in a decreased proliferative capacity of MPM
cells. In a cohort of MPM patient samples, high positivity for total MST1R by IHC
was an independent predictor of favorable prognosis. Additionally, elevated expression
levels of MST1 also correlated with better survival. This study also determined the
efficacy of LCRF-0004 and BMS-777607 in xenograft MPM models. Both LCRF-0004
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and BMS-777607 demonstrated significant anti-tumor efficacy in vitro, however BMS-
777607 was far superior to LCRF-0004. The in vivo and in vitro data generated by this
study indicates that a multi-TKI, targeting the MST1R/MET/TAM signaling pathways, may
provide a more effective therapeutic strategy for the treatment of MPM as opposed to
targeting MST1R alone.
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INTRODUCTION
Malignant Pleural Mesothelioma (MPM) is an
aggressive inflammatory cancer, associated with asbestos
exposure (1). The vast majority of patients present at an
advanced stage, and as a consequence overall survival is dismal,
with most patients dying within 1 year of diagnosis (2, 3).
Conservative estimates suggest that 43,000 people die from this
disease each year (4), however the actual number is probably
much greater (5, 6). Although, there have been some recent
advances in this disease, current standard of care (combination
of pemetrexed and cisplatin chemotherapy) (7) is non-curative
and results in a response rate of ∼40% (8). Consequently, there
is an urgent clinical need to identify novel therapeutic avenues in
this disease to improve patient outcomes.
Receptor tyrosine kinases (RTK) are critical signaling
mediators involved in key cellular regulatory pathways
such as proliferation and apoptosis (9). Several studies have
demonstrated that c-MET, Axl, EGFR, ErbB2, ErbB3, IGF1R, and
PDGFRβ RTKs are active in MPM (10–14), and that targeting
c-MET has anti-proliferative activity in this disease (10).
Récepteur d’origine nantais (RON/MST1R) is amember of the
MET proto-oncogene family, is involved in the development of
epithelial, bone, and neuro-endocrine tissues (15), and is essential
for complete embryonic development (16). A heterodimeric
protein, MST1R (RON) is composed of a transmembrane
150 kDa β chain and a 40 kDa extracellular α chain linked
by a disulphide bond (17). The main ligand for MST1R
(RON) is Macrophage Stimulating 1 (MST1), a member of
the Kringle family (18). Binding of MST1 (HGFL) results in
auto-phosphorylation and dimerization of MST1R (RON) (18).
A number of MST1R (RON) transcripts have been identified,
with the two most common having been identified in normal
and cancerous tissues including breast, prostate and lung (18),
coding for either full-length MST1R (RON) (flMST1R) or a
shorter transcript called short-form (sfMST1R) (19). sfMST1R
is constitutively phosphorylated and results in a more aggressive
cancer phenotype in breast cancer (19). A number of additional
MST1R (RON) variants have been identified, many of which
are constitutively active and have oncogenic potential including
RON1165 (also known as 1RON), RON1160, and RON1155
amongst others (18).
Once activated MST1R (RON) can signal through MAPK,
NF-κB, Src, PI3K/Akt (20), and β catenin (18). Pathological
activation of MST1R (RON) is involved in migration, invasion,
and the promotion of metastases (20, 21). The potential influence
of MST1R (RON) in oncogenesis is further enhanced by
the fact that it has now been shown to form heterodimers
with other receptors, such as IGF1R, EGFR, and MET
with resulting effects on cellular migration, invasiveness and
oncogenic transformation (11, 12, 19, 22). Additionally, MST1R
(RON) sustains MET oncogene addiction (23), while EGFR
dependence in non-small cell lung cancer (NSCLC) involves
MST1R (RON) (24).
The TAM receptors, comprising three RTKs, Tyro3, Axl,
and Mertk generally play important roles within the immune,
reproductive, hematopoietic, vascular, and nervous systems (25).
Altered TAM signaling is thought to contribute to chronic
inflammatory and autoimmune disease in humans, and is
strongly associated with cancer progression, metastasis, and
resistance to targeted therapies (25). Altered expression of AXL
has been previously demonstrated in MPM (13, 14). In MPM,
signaling through the PI3K/mTOR pathway has been shown
to be dependent on coordinated activation of EGFR, MET,
and AXL (26).
A number of compounds have been developed to target
either the MST1R (RON)/MST1 pathway, or multi-RTK
inhibitors designed to bind to the kinase domains of these
RTKs and inhibit their activity (some of which can inhibit
both MST1R (RON), c-MET, and members of the TAM
RTK family) and have recently been reviewed (18, 27). For
example, the dual MET/MST1R (RON) kinase inhibitor,
LY2801653 which is a type-II ATP competitive, slow-off inhibitor
binding to the kinase domains of these RTKs, decreased
tumor growth and angiogenesis in the lung cancer setting
and demonstrated greater efficacy than crizotinib (28). A five
amino acid peptide termed NRWHE is also a dual inhibitor
of c-MET/MST1R (RON) (27, 29). RON specific agents have
also been developed, such as the monoclonal antibodies Zt/f2
which functions by inducing RON internalization, subsequently
reduces RON expression and impairs downstream signaling
activation or Narnatumab ((IMC)-RON8) (Eli Lilly) which
acts by blocking RON binding to its ligand, macrophage-
stimulating protein (MSP), or the small molecule inhibitor of
MST1R (RON) called LCRF-0004 (N-(3-fluoro-4-(2-(1-methyl-
1H-imidazol-4-yl)thieno[3,2-b]pyridine-7-yloxy)phenyl)-1-
phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide) which
selectively binds to kinase catalytic domains of RON but not
MET (30–32).
Other small molecule inhibitors have been developed
(BMS-777607 and Merestinib), which whilst marketed
as MET inhibitors, have strong inhibitory effects on
MST1R (RON), Axl, and Tyro3 in an equivalent nM
range (33, 34).
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As the activation ofmultiple RTKs is a frequent event inMPM,
this study sought to examine and characterize the role of both
the MST1/MST1R (RON) and TAM RTK signaling pathways in
this disease. In addition, we determined the efficacy of targeting
these pathways using either agents that specifically target the
MST1/MST1R (RON) pathway ((IMC)-RON8, NRWHE and
LCRF-0004), or an agent that targets the MST1/MST1R (RON)
pathway, c-MET, Axl, and Tyro3 (BMS-777607).
RESULTS
The MST1R (RON)/MET/TAM RTKs Are
Frequently Activated in Mesothelioma and
Expressed in MPM Cell Lines
A phospho-RTK array was utilized to screen for activated RTKs
in a panel of MPM patient tumor samples (n = 7) and cell
lines (n = 4). Expression data indicated that c-MET (HGFR),
MST1R (RON), and members of the TAM receptors (namely
Axl and Tyro3, but not MERTK), were often activated in MPM
(Figure 1A, Supplementary Figure 1A). We therefore examined
the expression of MST1R, C-MET, AXL, and TYRO3 at the
mRNA level in a larger panel of MPM cell lines (n = 17). Both
fl and sfMST1R were robustly detected in the majority of MPM
cell lines at the mRNA level (Figure 1B), similar to the expression
of C-MET, TYRO3 andAXL (Figure 1B). Additionally, a number
MST1R (RON) β chain isoforms were detected at the protein level
such as p110 and p80 (Supplementary Figure 1B).
Overexpression of MST1R/MET/TYRO3
and AXL Is Frequent in Primary MPM
Strong expression of both sfMST1R and flMST1R mRNA was
also observed in fresh-frozen surgically resected mesotheliomas
across all histological subtypes (n = 17), which was greater than
that observed in resected benign tissues (n = 5) (Figure 2A,
Additional File: Figure S2A). We found the same was true
for the other receptors, with significant overexpression of C-
MET (Figure 2B, Figure S2B), AXL (Figure 2C, Figure S2C)
and TYRO3 (Figure 2D, Figure S2D) in the MPM cohort.
When stratified by histology, significant overexpression of
sfMST1R and flMST1R, C-MET, TYRO3, and AXL was
observed predominantly in the epithelial and biphasic subtypes
(Additional File: Supplementary Table S1).
Furthermore, the expression of 1RON (MST1R) (35), was
also detected in the majority of cell lines tested at the mRNA
level, and found to be significantly overexpressed in primary
patient tumors compared to benign pleura (Figures S3A–C,
Supplementary Tables S1, S2). As mutations within the tyrosine
kinase domain of MST1R have been identified in Merkel cell
carcinoma and Gastroesophageal adenocarcinoma (36, 37), we
screened DNA from our panel of MPM cell lines and the 17
fresh-frozen surgical samples for the presence of the R1018G
(36) or R1194H (37) mutations. No mutations were found (data
not shown). We also examined our panel of MPM cell lines and
tumors for the presence of MET exon 14 skipping, and again no
mutations were observed (data not shown).
Using Oncomine (38), we queried the expression of the
MST1R/C-MET/TYRO3 and AXL receptors in the Gordon
et al dataset (39) (Figure S4). We further examined an
available mesothelioma TCGA NGS dataset using cBioportal
(40) (Figure S4). Finally, we examined the expression of
these receptors in a separate series of patients for which
microarray data was available (Goparaju and Pass, unpublished)
(Figure S4). These in silico analyses demonstrate that the
MST1R and TYRO3 receptors are significantly overexpressed in
mesothelioma (Figure S4), confirming previous data regarding
MET (10) and AXL (13, 14), and suggesting that all four receptors
may be candidate targets for therapy in MPM.
MST1 Is Overexpressed in Primary MPM
Tumors and Cell Lines
We then examined the expression of the ligand for MST1R
(RON), MST1 in primaryMPM and cell lines. In patient samples,
MST1 mRNA was significantly elevated in the tumor specimens
(n= 17) compared to benign (n= 5; p< 0.0022; Figure 3A), with
significant overexpression observed in the epithelial and biphasic
subtypes (Supplementary Table S1). Analysis of the Gordon
dataset in Oncomine, subsequently confirmed the significantly
elevated MST1 expression in tumor tissues (Figure 3A). MST1
was found to be ubiquitously expressed at the protein level
in mesothelioma cell lines (Figure 3B). We also examined the
levels of MST1 in patient serums. Elevated MST1 was not
observed in patients with mesothelioma compared to at risk
(asbestos exposed) patients (Figure 3C). The TAM RTK ligand,
GAS6, was also not significantly altered at the mRNA level in
patients (Figure 3D).
MST1R (RON), Tyro3, and MST1 Expression
in MPM Tissues
It is well established that c-MET and Axl are overexpressed,
activated and have prognostic value in MPM tissues (14, 41),
however less is known about other family members. We stained
established MPM TMAs (n = 132) (42, 43) for expression of
MST1R (RON), MST1, and Tyro3.
Based on global staining intensity dichotomized closest to the
median into low and high, high expression of MST1R (RON) was
found to be an independent prognosticator for survival based
on Cox regression survival analysis (log rank p = 0.014, 14
vs. 11 months) (Figure 4A). Immunohistochemistry for MST1
was subsequently conducted on the same mesothelioma TMA
(Figure 4B). Like MST1R (RON), high MST1 expression was
found to be an independent prognostic factor for longer survival
(log rank p = 0.015, 14 vs. 11 months). There was no correlation
between gender, histology, or age with global RON or MST1
score. On multivariate analysis, only high expression of MST1
remained significantly associated with increased survival.
Expression of Tyro3 was also examined by IHC in a cohort of
MPM patients. In this instance, when staining was categorized
into positive and negative (with positive ≥10%), there was
a potential trend toward a survival benefit but this was not
significant (p= 0.052, 14.5 vs. 6.6 months) (Figure 4C).
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FIGURE 1 | MST1R (RON) is activated in MPM patient samples and cell lines. (A) A heat map summarizing the basal phosphorylation levels of the MET (HGFR),
MST1R (RON), and the TAM RTKs (TYRO3, AXL, and MERTK) in MPM tumors (n = 7) and cell lines (n = 4; Ju77, NCI-H28, NCI-H2052, ONE58). Signals with an
intensity value greater than the 99% confidence interval of the mean of the 10 negative controls were scored as positive. Yellow indicates high activity and blue
indicates low or undetectable kinase activity. (B) flMST1R and sfMST1R, MET, MST1, AXL, TYRO3, MERTK, and GAS6 were detected at the mRNA level (standard
end point PCR), in a panel of MPM cell lines, which included two normal mesothelial cell lines (LP9 and Met5A) (n = 17). 18S rRNA was used as a loading control.
In silico analysis of a mesothelioma TCGA dataset using
ProgGene (44) provides further evidence to support these
observations (Figure S5). In this data set only MST1R, MST1,
or AXL had any survival benefit. In agreement with our data,
high expression of MST1R (P < 0.022), or MST1 (P < 0.05)
was associated with better overall survival, which remained
significant (P < 0.008) under multivariate analysis (Figure S5).
High expression of AXL was associated with poorer overall
survival (P < 0.0000004), in contrast to the data observed by
Pinato et al. (14). All other genes examined had no significant
survival benefit (data not shown).
As MST1 plays important stimulatory roles with respect to
macrophages, TMAs were also stained with the macrophage
marker, CD68 (n = 130; Figure S6). However, there was no
relationship observed between CD68 staining and MST1 or any
patient characteristics. Similar results were also observed for in
silico analysis of the TCGA dataset (Figure S6).
In conclusion, these results suggest that these RTKs are
overexpressed in MPM and as such may be suitable candidates
for therapeutic intervention.
Recombinant MST1 Activates a Number of
Downstream RTK in MPM
To determine the activity of MST1-MST1R (RON) signaling
in MPM, JU77 cells were treated with MST1 (250 ng/mL)
for a period of 30min to 48 h and samples assayed on
a phospho-kinase array (46 sites; Figure S7). Densitometry
analysis was performed and fold increases were determined
relative to their expression at time 0. A significant number
of proteins were phosphorylated within 30min of MST1
treatment with a majority having sustained activation over
48 h. A number of these proteins are critical mediators of
the AKT/mTOR and ERK1/2 signaling pathways. In addition,
a number of these are downstream mediators, which can
be activated by MST1R (RON) through its cross talk with
EGFR, IGF-1R and MET (18). We further examined the
effect of MST1 on a second MPM cell line (NCI-H226)
(Figure S7). When compared across both cell lines a smaller
subset of phospho-kinases (predominantly limited to the
ERK and AKT signaling pathways) were activated by MST1
(Figure S7). Taken together, these results demonstrate the
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FIGURE 2 | mRNA levels of MST1R/MET/TYRO3 and AXL are elevated in a cohort of MPM patient samples. The mRNA expression of (A) MST1R, (B) MET, (C) AXL,
and (D) TYRO3 were examined by qPCR or standard end point PCR in a cohort of benign pleura (n = 4) vs. MPM patient specimens (n = 16). Because detection of
sfMST1R utilizes a nested-PCR methodology, densitometric analysis for this gene was used instead on end-point PCR products run on agarose gels, with 18S rRNA
serving as a loading control. Significant overexpression of all genes was observed in the MPM specimens compared with benign pleura. Statistical analyses used an
unpaired one tailed Student’s t-test with Welch’s correction (*p < 0.05, **p < 0.01).
functionality of MST1R signaling within the MPM setting,
affecting a number of critical downstream signaling pathways,
and further indicating that MST1R may be a potential target for
therapeutic intervention.
Inhibition of MST1R (RON) Significantly
Reduces Cellular Proliferation and Viability
We therefore examined whether MST1R (RON) blockade
had any effect on three cell lines (Met5A, JU77 and NCI-
H226) using three different approaches (i) LCRF-0004—a
MST1R (RON) specific small molecule inhibitor targeting the
MST1R (RON) RTK domain, (ii) NRWHE—a five amino
acid peptide sequence shown to prevent MST1R (RON)
ternary complex formation with CD44 and abrogating RON
or MET activation, and (iii) RON8—a humanized monoclonal
antibody directed against the extracellular domain of MST1R
(and acting to prevent MSP mediated signaling). The dose
response effect of these drugs on proliferation is provided in
(Figure S8). Intriguingly, LCRF-0004 was the only compound
found to significantly reduce the proliferative rate in NCI-
H226 MPM cells at both 24 (p < 0.01) and 48 h (p <
0.05) (Figure S8). Conversely, recombinant MST1 significantly
reduced the proliferative capacity of the normal Met5A pleural
cell line, while it had no meaningful effect on mesothelioma
cancer cells (JU77) (Figure S8). Based on these results, all
subsequent experiments utilized LCRF-0004 at 200 nM and
MST1 at 250 ng/mL. We subsequently determined the effect
of both drugs alone or in combination, on the proliferative
capacity of NCI-H226. LCRF-0004 treatment resulted in
significant anti-proliferative effects on the cells, which could
not be rescued by MST1 (Figure 5A). When cellular viability
was examined (Figure 5B), the same observations held at
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FIGURE 3 | Levels of MST1 are significantly elevated in MPM tissue vs. benign. (A) MST1 is overexpressed in primary MPM vs. benign pleura. Analysis of the
Leicester samples showed significant (p = 0.0022) overexpression in tumors (n = 17) vs. benign pleura (n = 5) Statistical significance was obtained using a two tailed
Student’s t-test with Welch’s correction (**p < 0.01). This data was confirmed using Oncomine analysis of the Gordon MPM dataset (n = 49) (37), where MST1 levels
were elevated in MPM tumors compared to pleural tissue (p = 0.018). For differential gene expression analysis Oncomine uses two sided Student’s t-test (36). (B)
MST1 is expressed at protein level in MPM cell lines (n = 12). Western blot demonstrating expression of MST1 at the protein level in MPM cell lines. (C) Serum MST1
levels were unaltered in patients with primary mesothelioma vs. patients with prior exposure to asbestos (n = 20 per group). (D) GAS6 mRNA levels were unchanged
in the MPM patient cohort compared with benign pleura. β-actin or 18S rRNA is included as a loading control in appropriate images.
24 h, however at 48 h, MST1 treatment also resulted in
decreased viability (Figure 5B UT vs. MST1). Again, MST1 was
unable to rescue the cells from the effect of the LCRF-0004
compound (Figure 5B).
Taken together, these results suggest that specifically
targeting the MST1R (RON) RTK domain has
anti-proliferative activity.
Inhibition of MET/MST1R (RON)/Tyro3 and
Axl Significantly Reduces Cellular
Proliferation
To determine if a multi-targeting approach was also potentially
useful, we examined the effect of varying doses of BMS-777607
on cellular proliferation. At 72 h post treatment, a significant
decrease in cellular proliferation was observed for MPM cells
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FIGURE 4 | In a cohort of MPM patient samples, elevated levels of MST1R (RON) and MST1 are associated with increased survival. (A) Immunohistochemical staining
of an MPM TMA for MST1R (Santa Cruz Biotechnology, sc-322, RRID: AB_677390), at (40x) magnification for both focal positive and strongly positive cores. Following
scoring by two pathologists, and dichotomized closest to the median into low and high using >2, </=2 global scores, the results were analyzed using Cox regression
for survival on (n = 132) patients for which clinical data was available. High expression of RON was found to be an independent prognostic factor correlating with an
overall increased survival (14 vs. 11 months, p = 0.014). (B) Immunohistochemical staining of an MPM TMA for MST1 (Santa Cruz Biotechnology, sc-6088, RRID:
AB_2235679). At (40x) magnification, both focal positive and strongly positive cores were observed. Following scoring by a pathologist and dichotomized closest to
the median into low and high using >2, </=2 global scores, the results were analyzed using Cox regression for survival on (n = 132) patients for which clinical data
was available. High expression of MST1 was found to be an independent prognostic factor correlating with an overall increased survival (14 vs. 11 months p = 0.015).
(C) Immunohistochemical staining of an MPM TMA for Tyro3 (Abcam ab79778, RRID: AB_10673822) in a patient tumor sample. (i) 20x negative control; (ii) 20x, and
(iii) 40x magnification of the inset highlighted in (ii). At (20x and 40x) magnification, both cytoplasmic/membranous staining is observed. When scored and categorized
into positive and negative with positive >= 10%, Kaplan-Meier Analyses (with OS from time of diagnosis) was not significant (14.5 vs. 6.6 months p = 0.052).
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FIGURE 5 | Treatment with LCRF-0004 and BMS-77607 reduces the proliferative capacity of malignant mesothelioma cells. (A) Effects of LCRF-0004 (200 nM) and
MST1 (250 ng/mL) (alone or in combination) on cellular proliferation as measured using a BrdU proliferation assay. LCRF-0004 significantly affects the proliferative
capacity of NCI-H226 cells at 24 or 48 h, while MST1 is unable to rescue the cells from the effect of RON inhibition. (B) Cellular viability is also decreased in response
to LCRF-0004 treatment (HCS assay) using the NCI-H226 cells. (C) Treatment with BMS-77607 resulted in significantly reduced cellular proliferation in both NCI-H226
and REN (MPM cell lines), whilst having no effect on LP9 (normal mesothelial cells). Significance was calculated based on a one-way ANOVA with a post-hoc Tukey’s
Multiple Comparison test (*p < 0.05; **p < 0.01; ***p < 0.001).
(NCI-H226 and REN) but not for the normal mesothelial cell line
(LP9) (Figure 5C), indicating that targeting all four RTKs is also
a potentially useful therapeutic strategy.
Obstruction of MST1R (RON) Signaling
Increases Cellular Apoptosis
As cellular proliferation and viability were affected by treatments
with LCRF-0004, we subsequently examined the effects of this
compound with respect to cellular apoptosis. Using a HCS
based assay, 200 nM of LCRF-0004 significantly increased cellular
apoptosis at both 24 and 48 h for early stage apoptotic cells
(apoptotic live) and at 48 h for late stage apoptotic cells (apoptotic
dead; Figure S9A). As was the case for proliferation and viability,
MST1 was unable to protect cells from the effect of the drug.
FACS was also used to assess apoptosis. Representative plots
and graphed analysis are shown in Figure S9B. A significant
increase in cellular apoptosis was observed at 48 h post
treatment (Figure 6A).
Inhibition of MST1R (RON) Alters Cell Cycle
Progression
Given that inhibition of MST1R (RON) can alter cellular
proliferation, viability, and apoptosis, this suggested that
inhibition of MST1R (RON) might alter cell cycle progression.
After 24 and 48 h of drug treatment, significant alterations to
cell cycle distribution were observed. Significantly altered cell
numbers were determined in either the G0/G1 phase (Figure 6B),
or in G2/M (Figure 6B), depending on the assay used, due to the
enhanced sensitivity of the FACS. MST1 did not alter cell cycle
progression, nor as was the case in other functional assays, could
it protect the cells from the effect of LCRF-0004.
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FIGURE 6 | LCRF-0004 promotes apoptosis and alters cell cycle progression in MPM cells (A) Inhibition of MST1R (RON) by LCRF-0004 (200 nM) promotes cellular
apoptosis in the NCI-H226 cell lines as measured by FACS (48 h post treatment). A representative FACS plots are show with the results graphed underneath
(MST1–250 ng/mL). Significance was calculated based on a one-way ANOVA with a post-hoc Tukey’s Multiple Comparison test. (**p < 0.01; ***p < 0.001). (B) FACS
analysis determined that LCRF-0004 (200 nM) treatments result in a significant accumulation of cells in the G2/M phase. Significance based on a one-way ANOVA
with a Tukey’s Multiple Comparisons test (**p < 0.01).
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FIGURE 7 | The multi-TKI, BMS-777607, results in superior tumor growth inhibition in vivo compared with LCRF-0004. Female nude Balb/c mice were injected sc.
with 7 million NCI-H226 cells and randomized in to treatment groups when tumors reached ∼200 mm3. Tumors were measured using digital calipers and the volume
calculated using the modified ellipsoid formula where the greatest longitudinal diameter (b) and the greatest transverse diameter (a) were used (a2 × b × 0.5). DMSO
was the vehicle control for both studies. (A) Mice were treated with 15 doses of drug (20 mg/Kg; n = 10) by i.p. injection over a 3 week period. Treatment started on
day 39 and finished on day 57 (Week 1: Days 39–43, Week 2: Days 46–50, Week 3: Days 53–57). Significant inhibition of tumor growth was observed between week
2 and 3. Animal data was analyzed using a two way ANOVA with Bonferroni adjustment with time treated as a discrete variable. Differences were considered
significant when p < 0.05. (B) Mice were treated with 21 doses of drug (5, 10, 25 mg/kg; n = 15), by oral gavage, over a 3 week period. Treatment started on day 21
and finished on day 39 (Week 1: Days 21–25, Week 2: Days 28–32, Week 3: Days 35–39) with significant tumor growth inhibition observed during the dosing period,
and tumor size measured following removal of drug until the experiment was stopped (day 61). Significance was measured using Restricted maximum likelihood
(REML) method (Tukey’s Multiple Comparisons test. ns - not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Further information is available in
Supplementary Table S3. (C) The animals were monitored up until day 110, and median survival calculated. Median survival was also greater, with it remaining
undefined for the 25 mg/kg group. Animal survival analysis was analyzed using Log-Rank (Mantel-Cox) test.
Inhibition of MST1R (RON) in vivo
Significantly Reduces MPM Tumor Volume
As LCRF-0004 showed promise in vitro, we subsequently
examined whether LCRF-0004 had similar efficacy in an in
vivo tumor xenograft model (NCI-H226 cells). Fifteen doses
were injected (I.P) over a 3 week period at three different
concentrations: 10, 15, and 20 mg/Kg. Tumor measurements
were taken every few days and all animals were euthanized
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when vehicle controls reached 1,500 mm3 (Day 61) (Figure 7A).
Little difference was observed in the lower dosing groups (10,
15 mg/Kg—data not shown), however significant inhibition of
tumor growth was observed on days 54 (384 vs. 666 mm3), 55
(404 vs. 710 mm3), 57 (460 vs. 734 mm3), and 61 (517 vs. 821
mm3) at the highest dose given (20mg/Kg vs. vehicle). These days
correspond to week three of treatment, whenmice were receiving
their 11th dose of the drug on day 54. To our knowledge, this is
the first data to demonstrate the in vivo efficacy of MST1R (RON)
blockade using LCRF-0004 in a murine model of mesothelioma.
Combined Inhibition of MST1R/MET/Tyro3
and Axl Is Superior to Inhibition of MST1R
Alone
Two orally bioavailable small molecule inhibitors have recently
been developed (BMS-777607 and Merestinib), which whilst
marketed as MET inhibitors, have strong inhibitory effects on
MST1R (RON), Axl, and Tyro3 in an equivalent nM range
(33, 34). We therefore examined the effect of BMS-777607 in
our NCI-H226 in vivo tumor xenograft model. Mice were dosed
orally at three concentrations which were administered daily
for 3 weeks. All three-drug concentrations showed significant
inhibition of tumor growth during the dosing period (days 21–
39), and following removal of drug until the experiment was
stopped (day 61) (Figure 7B). When survival was assessed, the
median survivals were as follows: 5 mg/Kg (101 days) vs. vehicle
(78 days) p = 0.0007; 10 mg/Kg (103 days) vs. vehicle (78
days) p < 0.0001; 25 mg/Kg (undefined) vs. vehicle (78 days)
p< 0.0001 (Figure 7C).
DISCUSSION
Receptor tyrosine kinase (RTK) oncogenic signaling networks
are becoming increasingly important, particularly in the light
of oncogene addiction and/or resistance to drug therapy.
Also known as the “Achilles’ heel” of cancer, oncogene
addiction basically describes a situation where the survival
and proliferation of a cancer is dependent upon an overactive
oncogene(s) or its downstream pathway(s). Consequently,
targeted disruption of this “addicted” oncogene/pathway leads
to growth arrest and programmed cell death (45, 46). Using a
phospho-RTK array, we screened a number of primary tumors
and cell lines for activated receptors. From this screen we
identified the c-MET RTK family, and members of the TAMRTK
family (Tyro3, Axl, MERTK), as being frequently activated in
MPM. While it is well established that the Hepatocyte Growth
Factor Receptor (MET) is frequently overexpressed and activated
in mesothelioma (10), to our knowledge this is the first indication
that it’s less well-studied family member, MST1R (RON) is also
frequently activated in MPM (Figures 1, 2).
MST1R (RON) can interact with both IGF-1R (47) and EGFR
(22) and it is interesting to note that all three were found activated
in 2/6 patient samples in our phosho-RTK array analysis, while
3/6 samples demonstrated co-activation of MST1R (RON) and
EGFR (Supplementary Figure S1). In this regard, EGFR and
MST1R (RON) have been linked to EGFR dependence in NSCLC,
as has IGF1R (24, 48, 49).
In this study we have shown that theMST1R, C-MET, TYRO3,
and AXL receptors are overexpressed in mesothelioma tumors
(Figure 2), as is MST1 (Figure 3), and independently validated
these results in various other available datasets (Figures S2–S4).
High expression of MST1R (RON) and its’ associated ligand
(MST1) is linked to longer survival (14 vs. 11 months) (Figure 4).
MST1 is an independent prognostic factor for longer survival
and in multivariate analysis only MST1 remained significant
for prognosis (Figure 4B). In silico analysis of the TCGA
mesothelioma dataset confirmed that high expression of MST1R
and MST1 was associated with longer survival (Figure S5).
Whilst surprising, higher expression of individual RTKs
often correlates with better prognosis. For example, in MPM,
overexpression of EGFR and plasma cell membrane MET
correlate with better survival (41, 50). Furthermore, high
expression of MST1R (RON) has been linked to cisplatin
resistance in ovarian cancer (51), a principle element in the
standard first-line chemotherapy for mesothelioma. Despite
these confounding issues, targeting of these RTKs may still have
potential benefit in the treatment of MPM.
In addition to MST1R (RON) itself, its’ ligand, MST1
plays critical roles in inducing the spreading, chemotactic
migration, and phagocytosis of macrophages (18). Staining of
our TMA for macrophage infiltration did not however find any
significant differences, and had no prognostic value (Figure S4),
while serum levels of MST1 also showed no significant
alterations between unaffected vs. tumor patients (Figure 3C).
When mesothelioma cells were stimulated with MST1, strong
effects on downstream signaling pathways were observed using
antibody based arrays, suggesting that this pathway is both
intact and functional in mesothelioma (Figure S5). Furthermore,
recombinant MST1 had significant anti-proliferative effects on a
normal pleural cell line, whilst having no effect on a malignant
cell line (Figure S6).
Given that JU77 cells seem to have a constitutive activation
of the RON MET TAM pathways due to the expression of the
sfMSTR1 variant (Figure 1 and Figure S1), it could be argued
that the responses to MST1 observed in this cell line (Figure S7)
do not truly reflect signaling functionality for this axis compared
to the responses observed for NCI-H226, and that cell lines
with different activation states of the pathway could instead
have been used to test the molecules to ensure that JU77 and
NCI-H226 are not “special cases,” or alternatively, cell lines with
similar activation states or characteristics could have been used
to confirm the results.
In this regard, it must be considered that c-Met and RON can
be activated by HGF andmacrophage stimulating protein (MSP),
respectively. Moreover, activated signaling also depends on the
availability of adaptor proteins and signaling intermediates or the
tendency of the adaptor proteins and signaling intermediates to
undergo homodimerization or heterodimerization. We therefore
examined the expression of both the MET/MST1R and TAM
signaling pathways in both cells and find that all of the ligands
and receptors are expressed at the mRNA level in both these cells
(Figure S10). The results that we have observed are consistent
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FIGURE 8 | Schematic diagram illustrating putative superior effects of multi-TKI inhibition. This figure represents how small molecule inhibitors such as LCRF which
are restricted to a single RTK are limited in their ability to target multi-TKIs if receptor hetero-dimerization occurs. In contrast, small molecule inhibitors such as
BMS-777607 can potentially target multiple homo-dimers and heterodimers simultaneously, giving superior results as observed in this study.
with other studies investigating the activation state of RTKs in
mesothelioma such as the study by Sekido et al. (11), which
also observed frequent coactivation of multiple RTKs in MPM
cells, but which differed between cell lines. MST1R and c-Met
are co-expressed in many types of tumors and functionally
crosstalk, forming heterodimers, and phosphorylating each other
(52, 53). Experimentally, it has been shown that c-Met has
stronger kinase activity than MST1R (54), and thus it is possible
that heterodimers might be more efficiently activated than
MST1R-MST1R homodimers, and implies that c-Met-MST1R
heterodimers can promote the activation of diverse signaling
cascades through different platforms (53).
As such the observed effects in both NCI-H226 and Ju77
reflects not only ligand binding of MST1 to full-length MST1R
homodimers but also reflects MST1 binding and signaling via
diverse RTK heterodimers (for example c-MET/MST1R), and the
subsequent effects of targeting RTKs either with TKI- specific
or multi-TKIs as shown in this manuscript and discussed below
must be considered in this light.
Interestingly, another RTK found to be highly activated
in our samples (5/7 tumor samples) was macrophage colony-
stimulating-factor-1-receptor MCSFR (CSF1R) (data not
shown). In this regard, Cioce et al. (55) recently determined that
CSF1R plays important roles in chemo-resistance in MPM. This
further strengthens the notion that receptors associated with
macrophage signaling may have critical roles in mesothelioma
pathogenesis, and it will be interesting in the future to determine
if MST1R (RON) could heterodimerize with this RTK.
Given that MST1R (RON) is overexpressed and activated in
MPM (Figures 1, 2), and that its ligand is also overexpressed
and functional in eliciting downstream signaling in MPM cells
(Figure 3 and Figures S7,S10), we subsequently assessed the
effects of three agents directed against MST1R (RON). The
first two compounds, a five amino acid peptide (NRWHE),
and Narnatumab ((IMC)-RON8) a monoclonal antibody being
developed by Eli Lilly had no significant responses on
mesothelioma cell lines, and were subsequently dropped from
further study (Supplementary Figure S8). Indeed, Eli Lilly has
discontinued development of Narnatumab (56). The poor
responses observed by Narnatumab or NRWHE may be because
both of these target elements of the MST1R (RON) receptor at
the extracellular or cell membrane level, and as MST1R (RON)
has several truncated receptor variants (lacking extracellular
elements) including the constitutively active oncogenic sfMST1R
(18), this may have limited their efficacy.
In contrast, a small molecule inhibitor of the MST1R (RON)
tyrosine kinase domain (LCRF-0004) had significant effects on
mesothelioma cellular proliferation and health, and cell cycle
progression (Figures 5–7), and additions of exogenous MST1
were unable to abrogate these effects. Following on from this
data, we examined if a multi-targeted approach would also
prove useful. BMS-777607 significantly reduced the proliferative
capacity of REN and NCI-H226, whilst having no obvious effect
on LP9 cells (Figure 5C).
The efficacy of both LCRF-0004 and BMS-77607 was
determined in an in vivo xenograft setting (Figure 7). Combined
inhibition of MST1R (RON)/MET/Tyro3 and Axl is superior
to inhibition of MST1R (RON) alone, with survival remaining
undefined for the 25 mg/kg dose of BMS-777607. The drug
optimization of LCRF-0004 is still ongoing and several new
analogs have been disclosed (57–59).
Mesothelioma lags behind most solid tumors with respect
to having very limited treatment options once standard
first line chemotherapy fails. We have identified a novel
pathway, the MST1/MST1R (RON) signaling axis, which is
overexpressed, activated, and can be targeted pharmacologically
in mesothelioma. However, our results suggest that a multi-TKI,
targeting the MST1R (RON)/MET/TAM signaling pathways may
be a more effective therapeutic strategy for the treatment of
MPM as opposed to targeting MST1R (RON) alone. This may
in part be due to a potential superiority of multi-TKI to target
receptor hetero-dimer formation and cross talk as postulated
Frontiers in Endocrinology | www.frontiersin.org 12 February 2019 | Volume 10 | Article 89
Baird et al. RON MET TAM in MPM
in Figure 8. One limitation to the current study is that only
a single MPM cell line was used for in vivo studies. As MPM
is a heterogenous disease (60), future studies involving other
mesothelioma cell lines or models may further delineate and
expand on this possibility.
Another limitation in the current study is that the in vivo
model used utilized subcutaneous flank xenograft models, which
do not truly reflect the growth pattern of malignant pleural
mesothelioma. Moving forwards, it may be necessary to use
orthotopic animal models to explore whether multi-TKIs are
more efficacious than single TKI based targeted therapy.
The results from this study suggest that receptor
heterodimerization may be an important element in malignant
pleural mesothelioma, particularly with respect to therapeutic
targeting. In this regard, whilst c-Met-RON heterodimers occur,
their functional relevance of has not been fully delineated.
However, some studies have suggested that general loss of
MST1R leads to changes in c-Met signaling. For example, it was
found that silencing RON in pancreatic cancer cell lines leads
to upregulation of c-Met expression and activity (61), whilst
another study has demonstrated that oncogenic addition to
c-Met requires co-expression of constitutively activated RON
that was dependent on transphosphorylation by c-Met (23). This
suggests that inhibitors that co-target or simultaneously block
the kinase activities of both c-Met and RON might be clinically
useful. However, most studies have not considered the possibility
that separately inhibiting either c-Met or RON might lead to
compensation by the other (53).
The potential for RTK cross talk is not only important in
carcinogenesis but may also be critical in drug resistance. A
recent study had shown that RTKs such as MET or AXL can
work together to drive resistance to EGFR-TKI in NSCLC (62).
Additionally, EGFR TKIs can produce off target effects such as
the inhibition of phosphorylation on specific residues in both
MET and MST1R (RON) (63).
Nevertheless, multi-TKIs are being studied as potential
therapeutic targets in cancer. The use multi-TKI such as that
used in this study (BMS-777607) which targets various RTKs at
equivalent low nanomolar concentrations should be considered
a useful tool to test whether receptor heterodimers play critical
roles in cancer development and drug resistance. Indeed, while
BMS-777607 is marketed as a c-MET inhibitor, one recent
study utilized it to therapeutically target AXL in a model
of glioblastoma (64).
The issue of receptor heterodimerization as a potential bypass
mechanism for lack of response to therapy (or in the development
of acquired or intrinsic resistance to therapy) by TKIs is
supported by the results obtained in this study. As such future
studies may have to include multiple in vitro and in vivo models
of MPM to test these possibilities more rigorously.
CONCLUSIONS
Our results have demonstrated that the MST1R/MET and TAM
receptors are overexpressed and may be suitable candidates for
therapeutic targeting inMPM.Our results suggest that multi-TKI
approaches with small molecule inhibitors targeting multiple
TKI domains at low nanomolar concentrations may have greater
therapeutic efficacy than agents which are selective for individual
RTKs alone. RTK hetero-dimerization is an emerging element in
our understanding of the causative mechanisms underpinning
resistance to targeted therapies. Multi-TKIs such as the one
studied, may have efficacy toward RTK hetero-dimers, and may
therefore overcome or limit the development of drug resistance
to targeted therapies involving TKIs. Moving forward it may be
possible to design a prospective clinical trial in mesothelioma
to target multi-RTK signaling pathways targeting the receptors
identified in this report.
MATERIALS AND METHODS
Primary Tumor Samples
Surgical specimens were obtained as discarded tumor
samples from patients who had undergone extended pleuro-
pneumonectomy at Glenfield Hospital, Leicester, UK. Benign
specimens were acquired from patients never diagnosed with
MPM. Informed consent was obtained from each patient, and
the study was conducted after formal approval from the relevant
Hospital Ethics Committee (Leicestershire REC references 6742
and 6948). Samples consisted of the following: 5 benign lesions
and 17 MPM samples (epithelioid: n = 7; sarcomatoid: n = 4;
biphasic: n= 6), details of which are provided in Table 1.
Ethics Statement
The study was conducted in accordance with the Declaration
of Helsinki.
TABLE 1 | Patient samples used in this study.
Sample Pathology (benign, epithelial,
biphasic, sarcomatoid)
Age Gender
JE29 Benign—pleural plaque 55 Male
JE30 Benign—pleural plaque 55 Male
JE32 Benign—pneumothorax 30 Male
JE41 Benign—empyema 68 Male
JE48 Benign—pleural plaque 55 Male
JE31 Epithelial 62 Male
JE139 Epithelial 73 Male
JE149 Epithelial 66 Male
JE155 Epithelial 56 Female
JE157 Epithelial 52 Male
JE162 Epithelial 56 Male
JE173 Epithelial 54 Male
JE86 Biphasic 54 Male
JE89 Biphasic 54 Female
JE136 Biphasic 41 Male
JE150 Biphasic 58 Male
JE151 Biphasic N/A Male
JE160 Biphasic 60 Female
JE106 Sarcomatoid 74 Male
JE125 Sarcomatoid 64 Male
JE133 Sarcomatoid 59 Male
JE145 Sarcomatoid (desmoplastic) 64 Male
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Fresh Frozen Samples: Study was conducted after formal
approval from the relevant Hospital Ethics Committee
(Leicestershire REC references 6742 and 6948). All subjects
gave their written informed consent for inclusion before they
participated in the study.
TMAs: Zurich. The construction of the TMA was conducted
after formal approval from the relevant Hospital Ethics
Committee (Stv.29-2009). Sydney. Ethical approval was obtained
from the Human Research Ethics Committee at Concord
Repatriation General Hospital, Sydney.
Animal Studies: All animal studies were approved by
the relevant institutional Animal Research Ethics Committee
(AREC) (AREC789 and AREC1039) at the Royal College of
Surgeons in Ireland (RCSI) and were licensed by the Department
of Health and Children (B100/3654).
TMA Immunohistochemistry and Analysis
Two sets of TMAs were used in this study. The first comprises a
set of three tissue microarrays (TMA) of n = 352 patients with
MPM (40), and the second TMA had n= 80 MPM patients (41).
Further details on staining, data interpretation, and statistical
analysis are provided in Supplementary Materials and
Methods S1.
Cell Culture
All MPM cell lines were maintained in a humidified atmosphere
containing 5% CO2 in appropriate media supplemented with
10% Fetal Bovine Serum and penicillin streptomycin (500
U/mL). Cell culture reagents were purchased from Lonza
(Walkersville, MD, USA). The following MPM cell lines were
used in the study: LP9, Met5A, NCI-H2596, MMP, MMB,
NCI-H2052, NCI-H28, Ju77, One58, RS-5, DM-3, ACC-MESO-
1, ACC-MESO-4, Y-MESO-8D, Y-MESO-9, Y-MESO-12, Y-
MESO-14, REN, NCI-H226, and MSTO-211H. ACC-MESO-1,
ACC-MESO-4, Y-MESO-9, and Y-MESO-12 were generously
provided by Yoshitaka Sekido, (Aichi Cancer Center Research
Institute, Japan). NCI-H2052, One-58, and Ju77 cells were
provided by Duncan Stewart (University of Leicester, UK). LP-
9, MMB, and MMP were a generous gift from Warren Thomas
(Royal College of Surgeons in Ireland, Dublin, Ireland). The
REN and NCI-H226 cell lines were provided by Dean Fennell
(Queen’s University, Belfast, Northern Ireland). NCI-H28, and
the immortalized non-tumorigenic mesothelial cell line, Met-5A
were purchased from the ATCC (LGC Promochem, Teddington,
UK). STR profiling of the NCI-H226 was conducted by Source
Bioscience (Nottingham, UK) to confirm that the cell line had
the correct genotype.
Drugs and Drug Treatments
Cells were serum starved (0.5% FBS) for 24 h before the addition
of drugs and/or recombinant ligand. LCRF-0004 (32) was
provided by Dr. Stéphane Raeppel (ChemRF Laboratories, QC,
Canada), and dissolved in DMSO. (IMC)-RON8 was provided
by Genentech/Eli Lilly (IN, USA) in PBS. NRWHE, a small
five amino acid peptide (29) was synthesized for this study by
Biomatik (Biomatik Corp., ON, Canada) and re-suspended in
sterile water. Recombinant human MST1 was obtained from
R & D Systems (MN, USA) and re-suspended in sterile PBS
containing 0.1% BSA w/v. BMS-777607 was purchased from
Selleck (Munich, Germany) and dissolved in DMSO.
RNA Isolation and RT-PCR Amplification
Total RNA was extracted using TRI reagent R© (Molecular
Research Center, OH, USA) according to manufacturer’s
instructions. Prior to first strand cDNA synthesis, 10 µg of total
RNA was pre-treated by digestion with RQ1 DNase (Promega,
WI, USA) according to the manufacturer’s instructions.
cDNA was generated using RevertAid (Thermo Scientific,
Leicestershire, UK) and Oligo dT(20) primers (Eurofins MWG
Operon, Ebersberg, Germany) according to the manufacturer’s
instructions. Cell lines and fresh-frozen samples were examined
for the expression of full length (fl) MST1R, short form (sf)
MST1R, 1RON, MST1, AXL, TYRO3, GAS6, 18S rRNA, and
Beta-actin by either standard end point PCR, using primers and
annealing temperatures outlined in Table 2 or qPCR. Cycling
conditions for amplification of sfMST1R and flMST1R were as
described previously (19). PCR cycling conditions for all others
were as follows: 1min at 95◦C, 1min at the appropriate annealing
temperature as outlined in Table 2, 1min at 72◦C, for 35 cycles,
with a final extension of 72◦C for 10min. RT-PCR products for
each experimental gene and appropriate housekeeping genes
(Beta actin or 18S rRNA) were run on 1% agarose gels. Following
image capture, product quantification was performed using
TINA 2.09c (Raytest, Isotopenmeßgeräte GmbH, Straubenhardt,
Germany) densitometry software. The mRNA expression was
normalized to loading controls, and was expressed as a ratio of
target mRNA expression: loading control expression.
Analysis of mRNA Expression by qPCR
Validation of RT-PCR results was subsequently confirmed using
SYBR green based quantitative real-time PCR. First-strand cDNA
was prepared from 1 µg of total RNA using RevertAid reverse
transcriptase (Thermo Scientific) according to themanufacturer’s
instructions. Prior to reverse transcription, the RNA was treated
with amplification grade DNase I (Sigma-Aldrich) according to
the manufacturer’s instructions. PCR reactions were carried with
the primers as shown in Table 2.
MPM patient samples were assessed for suitability for qPCR
analysis. Of the original samples (n = 4) benign and (n = 16),
tumor samples were found to be of sufficient quality, and qPCRs
were subsequently conducted on these samples using an Illumina
Eco qPCR and GoTaq R© qPCR Master Mix (Promega) with a
2-step qPCR program having the following cycling parameters:
An initial Polymerase activation of 95◦C for 2min followed
by 35 cycles of 95◦C 15 s and annealing/amplification 61◦C for
1min. A melting curve analysis was conducted at the end of each
PCR using 95◦C 15 s, 55◦C 15 s, and a final 95◦C for 15 s. Data
was analyzed using either the default in-built Eco software or
imported into EcoStudy (Illumina).
Mutation Screening
Mutation screening for cMET exon14 skipped cells was
conducted by end-point PCR of mRNA from patients and cell
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lines using primers in Table 1, designed to span exons 13–15.
PCR products were run out on a 2% agarose gel.
Mutations in Exon13 and Exon17 of MST1R were analyzed
using previously published primers (Table 2) (36, 65). PCR
was conducted on patient genomic DNA, and the PCR
products were purified and sent for sequencing to a commercial
provider (Source Bioscience).
Protein Isolation and Western
Immunoblotting
Total protein was isolated from cell cultures using TRI reagent R©
(MRCgene) according to manufacturer’s instructions. Lysates
were separated by SDS/PAGE and subsequently transferred
onto a PVDF membrane. Membranes were subsequently
probed for expression of the alpha and beta subunits of
MST1R (RON α/RON-β), MST1, αβtubulin, or β-actin.
Secondary antibodies were HRP labeled and bound antibody
complexes were detected using the Supersignal West Pico
Chemiluminescent kit (Pierce, IL, USA). Complete details of
antibodies and methods are provided in Supplementary file
(S1 Supplementary Materials and Methods).
Immuno-Precipitation of MST1
OnemL cell culture supernatant was removed from each cell line,
and MST1 immuno-precipitated using anti-MST1 (Santa Cruz)
and Protein G PLUS-Agarose beads. Refer to supplementary
file S1 (S1-Supplementary Materials and Methods) for
further details.
Protein Arrays
JU77 cell lines were treated with MST1 at a final concentration
of 250 ng/mL for a period of 0, 30min, 24, and 48 h. In an
additional experiment, NCI-H226 cells were treated as follows:
(i) Untreated, (ii) MST1 (250 ng/mL) for 30min, (iii) LCRF-
0004 (200 nM) for 3 h, and (iv) MST1 and LCRF-0004 combined.
Protein lysates were collected and 300 µg assayed on a Proteome
Profiler
TM
Phospho-Kinase Array (R&D Systems) according to
the manufacturers’ instructions. These arrays contain antibodies
to 42–46 kinase phosphorylation sites, spotted on the array
in duplicate. In addition, the arrays contain both positive and
negative controls. Product quantification was performed using
TINA 2.09c (Raytest, Isotopenmeßgeräte GmbH, Straubenhardt,
Germany) densitometry software.
TABLE 2 | Primers and associated annealing temperatures.
Gene Primer sequence Annealing temp. (◦C) Source
sfMST1R F: (P1) 5′-CCTCATGACCCTCTTCTGCAGT-3′ 56 (19)
F: (P2) 5′-CAGCAGTGGCACACAGGAT-3′
R: (P4) 5′-GCCACCAGTAGCTGAAGACC-3′
flMST1R F: 5′-TATCCTGCAGGTGGAGCTG-3′ 56 (19)
R: 5′-ATGAAATGCCATGCCCTTAG-3′
MST1 (MSP) F: 5′-TGTTCCAGAACCCACAGCAT-3′ 58 This study
R: 5′-CCCTCAGTGCACATCTCACT-3′
MST1R Ex13 mutation F: 5’-CTTCCTCCCAACCTGAATGA-3′ 60 (34)
R: 5′-GGAATCCAGACCATCAATGG−3′
MST1R Ex17 mutation F: 5’-TTGCCCACCAACCCACCTGTG-3′ 64 (59)
R: 5′-CACCCCAGCTACTCTGGACTC-3′
1RON F: 5′- CCTGAATATGTGGTCCGAGACCCCCAG-3′ 56 (33)
R: 5′-CTAGCTGCTTCCTCCGCCACCAGTA-3′
18S rRNA F: 5′-GATGGGCGGCGGAAAATAG-3′ 58
R: 5′-GCGTGGATTCTGCATAATGGT-3′
Beta actin F: 5′-TGTTTGAGACCTTCAACACCC-3′ 56 (64)
R: 5′- AGCACTGTGTTGGCGTACAG-3′
c-METExon14 mutation F: 5′- TTGCTGGTGTTGTCTCAATATCAAC-3′ 58 This study
R: 5′-GTTAGGATGGGGGACATGTCTG-3′
c-MET F: 5′-TACCCCAGCCCAAACCATTT-3′ 58 This study
R: 5′-CAACACCTGTTATTGTGCTCCC-3′
TYRO3 F: 5′-GAGAGGAACTACGAAGATCGGG-3′ 58 This study
R: 5′-AGTGCTTGAAGGTGAACAGTG-3′
AXL F: 5′-GTGGGAGATTGCCACAAGAG-3′ 58 This study
R: 5′-CTTCCCGCAGCTCTGTAAAAC-3′
MERTK F: 5′-TTCTCAGTGAGGCAGCGTGC-3′ 58 This study
R: 5′-TGGTCCTGTCTCCAATCGGG-3′
GAS6 F: 5′-AAGTCGTGGCTCACATCCGC-3′ 58 This study
R: 5′-TCTCCATTAGGGCCAAGGCC-3′
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Proliferation Assays
Cell proliferation was measured using either a Cell Proliferation
BrdU ELISA (Roche Diagnostics Ltd., Sussex, UK) according
to the manufacturer’s instructions, or by a Resazurin reduction
based assay (66).
For BrDU based assays, cells (JU77, Met5A, and NCI-
H226) were seeded at 2.5 × 103/well in a 96-well plate.
Following overnight incubation, cells were treated for 24 or
48 h with human recombinant MST1 (0–250 ng/mL), LCRF-
0004 (0–200 nM), RON8 (200–1,000 ng/mL), or NRWHE (25–
200 ng/mL) or combinations of drug as appropriate. Absorbance
was measured on a plate reader at 450 nm with a reference
wavelength set to 690 nm. Untreated wells were used for
normalization purposes and set to 100%.
For Resazurin based assays cells (LP9, NCI-H226, and REN)
were seeded at 3.5 × 103/well in a 96 well plate. Following
overnight incubation, cells were serum depleted by replacing the
media with freshmedia containing 0.5% FBS and left for a further
24 h. Subsequently, cells were treated for 72 h with combinations
of drug as appropriate. Resazurin was added after the 72 h
treatment period, and following incubation for approximately
4 h at 37◦C, fluorescence was measured on a fluorescence plate
reader using a 560 nm excitation/590 nm emission filter set.
Cellular Viability and Apoptosis (High
Content Analysis)
NCI-H226 cells were seeded at 2.5 × 103/well in a 96-well
plate and adhered overnight. Cells were treated for 24–72 h
with human recombinant MST1 (250 ng/mL) and LCRF-0004
(200 nM) alone or in combination. Refer to supplementary
file S1 (S1-Supplementary Materials and Methods) for detailed
methods on HCA assays.
Cellular Apoptosis (FACS)
NCI-H226 cells were seeded in 6-well plates at a
density of 1 × 105 cells per well and were allowed to
adhere overnight. Cells were treated with appropriate
concentrations of drug, diluted in cell culture media, for
48 h. Additional details can be found in Supplementary file S1
(S1-Supplementary Materials and Methods).
Cell Cycle Analysis (Cytell)
NCI-H226 cells were seeded at 2.5 × 103/well in a 96-well
plate and adhered overnight. Cells were treated for 24–48 h
with human recombinant MST1 (250 ng/mL) and LCRF-0004
(200 nM) alone or in combination. Cells were stained for 45min
at 37◦C using the Cytell Cell Cycle Kit (GE Health Bio-sciences),
imaged on the Cytell and analyzed, and quantified using the Cell
Cycle BioApp (GE Health Bio-sciences).
Cell Cycle Analysis (FACS)
NCI-H226 cells were seeded at 1 × 105 cells and allowed to
adhere overnight. Subsequently, they were treated with either
DMSO (vehicle control) or LCRF-0004 (200 nM) for 24 and
48 h. Additional details are provided in Supplementary file S1
(S1-Supplementary Materials and Methods).
Xenograft Murine Model
All work was performed at the Royal College of Surgeons
in Ireland RCSI Biomedical Research Facility (BRF) under
Department of Health and Children license #B100/3654 and
under RCSI Animal Research Ethics Committee (AREC)
approvals (AREC789 and AREC1039). Seven million NCI-H226
cells suspended in 100 ul of serum-free RPMI medium were
subcutaneously injected into the right flank of female Balb/c
nude mice (Charles River Laboratories, Kent, UK). Tumors were
measured using digital calipers and the volume calculated using
the modified ellipsoid formula where the greatest longitudinal
diameter (b) and the greatest transverse diameter (a) were used
(a2 × b × 0.5). When palpable tumor reached approximately
200 mm3, the mice were randomly assigned into appropriate
treatment groups. The groups consisted of two separate studies
as follows: Study 1—vehicle control (DMSO), LCRF-0004 at
20 mg/Kg (n = 10 per group). LCRF-0004 and DMSO were
administered via IP injection with each animal receiving 15 doses
of treatment, following a Monday-Friday schedule for 3 weeks in
total. Study 2—vehicle control (DMSO) (n= 14), BMS-777607 at
5, 10, and 25 mg/Kg (n= 15 per drug group).
Dosing was determined as follows: LCRF-0004 toxicity data
was provided by ChemRF Laboratories which had previously
determined that a dose of 20 mg/kg for 14 days resulted in
observed anti-tumor activity without any mortality or body
weight changes occurring. Using this as a guide, this a 20 mg/kg
daily dose was chosen for the experiments shown in Figure 7A.
For the studies using BMS-777607 a similar approach was
used. Pre-existing animal data BMS-777607 at doses ranging
from 6.25 up to 50 mg/kg has previously been used in GTL-
16 human tumor xenografts in athymic mice. The drug was
administered orally once daily for 14 consecutive days. The
authors reported that the drug was active at all dose levels tested
and complete tumor stasis was observed at doses 25 and 50
mg/kg. No overt toxicity was observed at any of these levels as
defined by weight loss or morbidity. BMS-777607 at doses 10
and 25 mg/kg has also been used in metastatic mouse tumor
model in C3H/HeJ mice. Authors reported that neither 10 nor
25 mg/kg when given orally once daily for 15 days resulted in a
significant body weight loss throughout the course of experiment
(33, 67). Using these two studies as a guide we used 3 different
concentrations of drug to determine which is the most effective
in inhibiting tumor growth with the maximum dose at 25 mg/kg.
For both studies drug was administered orally for 3 weeks on
a daily basis (21 doses of drug). All animals were sacrificed when
vehicle controls and/or tumors reached 15mm in any diameter.
In silico Analysis
In silico analysis was conducted on three additional
mesothelioma datasets as follows:
(a) the dataset previously published by Gordon et al. (39),
which was interrogated using Oncomine, (b) the TCGA data set,
and (c) existing unpublished mesothelioma affymetrix datasets
(Goparaju and Pass, unpublished). Data-mining of available
mesothelioma datasets were conducted using Oncomine 1(38),
1Oncomine. Available: www.oncomine.org [Accessed].
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cBioportal 2(40), or PROGgeneV2 (3(44)), using their respective
default settings.
Statistical Analysis
All data are expressed as mean ± SEM unless stated otherwise.
Statistical analysis was performed with either Prism 5.01 or
Prism 6 (GraphPad, Ca, USA) using either paired two-tailed
Student’s t-test or the Mann-Whitney two-tailed t-test. One-
way analysis of variance (ANOVA) was used where groups in
the experiment were three or more. Following ANOVA, post-
test analyses utilized either the Tukey multiple comparisons
test, or the Dunnett’s multiple comparison test. Animal tumor
volume data was analyzed using either a two way ANOVA with
Bonferroni adjustment with time treated as a discrete variable,
or by a restricted maximum likelihood (REML) method using
Tukey’s Multiple Comparisons test. Differences were considered
significant when p< 0.05.
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